Few topics in contemporary psychiatry generate as much fascination, hope, and discomfort as the therapeutic use of psychedelics.For some, they represent a long-awaited disruption in the treatment of depression, a field in which many patients still experience partial response, relapse, or treatment resistance despite decades of
European Journal of PharmacologyApril 5, 2017James Oluwagbamigbe Fajemiroye, Polepally Reddy Prabhakar, Luiz Carlos da Cunha et al.
The increasing cases of depression has made the searches for new drugs and understanding of the underligning neurobiology of this psychiatric disorder a necessity. Here, we modified the structure of salvinorin A (a known halucinogen) and investigated antidepressant-like activity of its four derivatives; 22-methylsulfanylsalvinorin A(SA1), 2-O-cinnamoylsalvinorin B (CSB), 22-azidosalvinorin A...